Referral for cancer genetics consultation: a review and compilation of risk assessment criteria

被引:114
作者
Hampel, H
Sweet, K
Westman, JA
Offit, K
Eng, C
机构
[1] Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43221 USA
[2] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43221 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, New York, NY 10021 USA
关键词
D O I
10.1136/jmg.2003.010918
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: There have been many papers on the diagnostic criteria for specific hereditary cancer susceptibility syndromes and the likelihood that an individual has a germline mutation in one of the various cancer susceptibility genes. To assist health care professionals in deciding when a cancer genetics consultation is appropriate, available reports were critically reviewed in order to develop a single set of risk assessment criteria. Methods: The criteria were based on a comprehensive review of publications describing diagnostic criteria for hereditary cancer syndromes and risk to first degree relatives of cancer patients. Priority was given to diagnostic criteria from consensus statements ( for example, those from the National Comprehensive Cancer Network). Expert opinion from study personnel was then used to adopt a single set of criteria from other publications whenever guidelines differed. Results: Based on family history, a set of criteria was developed to identify patients at risk for a hereditary cancer susceptibility syndrome, patients with moderate risk who might benefit from increased cancer surveillance, and patients who are at average risk. The criteria were applied to 4360 individuals who provided their cancer family history between July 1999 and April 2002, using a touch screen computer system in the lobby of a comprehensive cancer centre. They categorised an acceptable number of users into each risk level: 14.9% high risk, 13.7% moderate risk, and 59.6% average risk; 11.8% provided insufficient information for risk assessment. Conclusions: These criteria should improve ease of referral and promote consistency across centres when evaluating patients for referral to cancer genetics specialists.
引用
收藏
页码:81 / 91
页数:11
相关论文
共 74 条
[1]   Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease [J].
Aaltonen, LA ;
Salovaara, R ;
Kristo, P ;
Canzian, F ;
Hemminki, A ;
Peltomäki, P ;
Chadwick, RB ;
Kääriäinen, H ;
Eskelinen, M ;
Järvinen, H ;
Mecklin, JP ;
de la Chapelle, A ;
Percesepe, A ;
Ahtola, H ;
Härkönen, N ;
Julkunen, R ;
Kangas, E ;
Ojala, S ;
Tulikoura, J ;
ValKamo, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) :1481-1487
[2]  
*ACMG NYS HLTH DEP, 1999, GEN SUSC BREAST OV C
[4]   Assessing the risk of breast cancer. [J].
Armstrong, K ;
Eisen, A ;
Weber, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :564-571
[5]   Graphs to estimate an individualized risk of breast cancer [J].
Benichou, J ;
Gail, MH ;
Mulvihill, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :103-110
[6]   A COMPUTER-PROGRAM FOR ESTIMATING INDIVIDUALIZED PROBABILITIES OF BREAST-CANCER [J].
BENICHOU, J .
COMPUTERS AND BIOMEDICAL RESEARCH, 1993, 26 (04) :373-382
[7]   Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [J].
Berry, DA ;
Parmigiani, G ;
Sanchez, J ;
Schildkraut, J ;
Winer, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :227-238
[8]   Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43 [J].
Berthon, P ;
Valeri, A ;
Cohen-Akenine, A ;
Drelon, E ;
Paiss, T ;
Wöhr, G ;
Latil, A ;
Millasseau, P ;
Mellah, I ;
Cohen, N ;
Blanché, H ;
Bellané-Chantelot, C ;
Demenais, F ;
Teillac, P ;
Le Duc, A ;
de Petriconi, R ;
Hautmann, R ;
Chumakov, I ;
Bachner, L ;
Maitland, NJ ;
Lidereau, R ;
Vogel, W ;
Fournier, G ;
Mangin, P ;
Cohen, D ;
Cussenot, O .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (06) :1416-1424
[9]  
BIRCH JM, 1994, CANCER RES, V54, P1298
[10]  
BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO